CFTR and cystic fibrosis: The search for CF therapeutics has allowed the identification of two classes of small-molecule modulators able either to improve the permeation of ions through the CFTR pore (namely potentiators), binding directly to mutant CFTR, or to promote the delivery of the processing-defective CFTR protein to the PM (namely correctors), acting as pharmacological chaperones or, eventually, as regulators of proteostasis [23].